Some of the most powerful innovation in healthcare doesn’t come from inventing new drugs at all it comes from looking again at the ones we already have.
For decades, drug affordability has been framed almost entirely as a low and middle income country (LMIC) problem a question of access in resource poor settings. That framing is incomplete. Today the affordability crisis is global and patient centric rather than geography specific. In high-income countries (HIC), rising numbers of underinsured patients, high deductible plans, and steep out of pocket costs mean patients in wealthy economies routinely ration medication or forgo treatment altogether. A cancer patient in the United States skipping a dose to stretch a prescription, and a tuberculosis patient in a low resource setting unable to access treatment at all, face the same underlying failure: the cost of innovation has outpaced the ability to pay for it.
This is precisely why drug repurposing deserves far more attention than it currently receives. It isn’t a stopgap for poorer health systems, it is one of the most patient centric strategies available to the entire global healthcare industry.
The Economics That Make Repurposing Powerful
Building a drug from the ground up is a brutal numbers game: more than ten years, upwards of a billion dollars, and most candidates never reaching a patient. Repurposing sidesteps that math almost entirely. Rather than starting from a blank slate, it asks a more practical question: a medicine already approved, already produced at scale, already shown safe in real patients, might it also treat something else? The manufacturing lines are running, the safety record is on file, and the cost of goods rarely comes close to what a brand-new therapy demands. What this path calls for isn’t a fresh molecule, it’s fresh evidence and the willingness to see familiar tools in a new light.
Extraordinary Examples Already Changing Lives
The track record of repurposing spans nearly every therapeutic area, and includes some of the most consequential medical discoveries of the last century.
Zidovudine (AZT) was originally developed as a cancer treatment in the 1960s and shelved for poor efficacy. Two decades later, it became the first antiretroviral approved for HIV/AIDS, arriving when the epidemic had no treatment options at all.
Thalidomide, once withdrawn from the market after catastrophic birth-defect outcomes in the 1960s, was later found to be remarkably effective against multiple myeloma and leprosy-related complications, and today remains a standard-of-care option in blood cancer treatment under strict safety protocols.
Propranolol, a decades-old beta-blocker for hypertension, was found almost by accident to shrink infantile hemangiomas, a common vascular birthmark in babies and is now first-line treatment for that condition, replacing more invasive surgery.
Each shares a common thread: the innovation was not a new chemical entity, but a new use for one already known, trusted, and affordable reaching patients facing conditions with few other options.
Why This Matters for Every Health System
The instinct across the pharmaceutical industry is to equate innovation with novelty a new compound, a new device, a new platform. But some of the most meaningful innovation lies in re-examining what already exists.
For LMIC health systems, repurposing offers a viable path to treatment for diseases long neglected commercially, such as tuberculosis, where market size alone will never justify developing an entirely new therapy. For HIC health systems, it offers something equally critical: a way to lower the cost of care for insured and uninsured patients alike, at a time when out-of-pocket spending is rising and trust in the system’s affordability is eroding.
This is where open, collaborative research becomes essential. Repurposing often falls outside the commercial incentives that drive conventional pharma R&D an already-approved, off-patent drug offers little exclusivity to justify traditional development pathways. Progress depends instead on academic institutions, non-profits, public health bodies, and companies sharing data and running trials collaboratively across borders, rather than working in siloed isolation.
A Broader Definition of Innovation
As healthcare systems worldwide grapple with rising costs and unequal access whether that shows up as a lack of insurance in a high income country or a lack of market incentive in a low income one, repurposing offers a path to progress that is faster, cheaper, and inherently more equitable by design.
This isn’t a call to abandon the search for new treatments; novel science remains essential. But it is a call to widen the industry’s definition of innovation to include better use of what already exists. The next major breakthrough for patients uninsured in a wealthy country or underserved in a low-resource one may not come from a new molecule at all. It may already be sitting on a pharmacy shelf, waiting for someone to ask the right question.
